Profile data is unavailable for this security.
About the company
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
- Revenue in BRL (TTM)1.69bn
- Net income in BRL187.05m
- Incorporated1987
- Employees1.90k
- LocationBlau Farmaceutica SARodovia Raposo Tavares2833, km 30,5, Barro BrancoCOTIA 06.705-030BrazilBRA
- Phone+55 1 146159400
- Fax+55 1 146159401
- Websitehttps://www.blau.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | 1.09bn | -366.47m | 2.73bn | 377.00 | -- | -- | -- | 2.51 | -0.4388 | -0.4388 | 1.30 | -0.1901 | 0.5775 | 0.8389 | 4.30 | 496,978.80 | -19.45 | -43.60 | -26.81 | -56.57 | 81.36 | 78.23 | -33.69 | -143.08 | 1.29 | -1.86 | 1.14 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| SIGA Technologies Inc | 1.01bn | 497.68m | 2.74bn | 45.00 | 5.57 | 2.78 | 5.47 | 2.72 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Theravance Biopharma Inc | 360.11m | -265.09m | 2.75bn | 99.00 | -- | 2.44 | -- | 7.64 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Canopy Growth Corp | 1.16bn | -2.43bn | 2.75bn | 1.03k | -- | 1.02 | -- | 2.36 | -6.98 | -6.73 | 3.32 | 5.43 | 0.1934 | 2.17 | 6.16 | 272,590.90 | -40.38 | -26.08 | -48.35 | -28.67 | 31.47 | 2.59 | -208.81 | -333.29 | 1.07 | -0.2973 | 0.5462 | -- | -10.83 | 5.59 | 84.29 | -- | -64.60 | -- |
| Rigel Pharmaceuticals Inc | 914.39m | 22.54m | 2.80bn | 147.00 | 126.50 | -- | 83.18 | 3.06 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| ChengDu Sheng Nuo Biotec Co Ltd | 387.05m | 74.32m | 2.80bn | 1.13k | 37.61 | 3.80 | -- | 7.24 | 0.8279 | 0.8279 | 4.31 | 8.20 | 0.3401 | 0.862 | 3.96 | 426,977.70 | 6.52 | 7.47 | 8.67 | 9.44 | 59.92 | 70.52 | 19.17 | 15.82 | 0.8466 | 13.35 | 0.32 | 21.83 | 9.93 | 9.37 | 9.08 | 18.69 | 54.71 | -- |
| Blau Farmaceutica SA | 1.69bn | 187.05m | 2.81bn | 1.90k | 15.01 | 1.33 | 11.99 | 1.67 | 1.04 | 1.04 | 9.40 | 11.80 | 0.5339 | 1.82 | 3.59 | 887,276.30 | 5.81 | 16.01 | 6.79 | 19.59 | 35.38 | 44.57 | 10.88 | 21.99 | 2.27 | 13.12 | 0.2086 | 16.61 | -2.44 | 11.91 | -31.14 | 15.18 | 38.96 | -- |
| Solara Active Pharma Sciences Ltd | 840.38m | -368.76m | 2.84bn | 2.16k | -- | 2.46 | -- | 3.37 | -137.13 | -137.13 | 320.29 | 301.63 | 0.4731 | 1.77 | 2.69 | 5,667,023.00 | -20.76 | -2.44 | -36.40 | -3.84 | 38.70 | 41.16 | -43.89 | -4.49 | 0.448 | -1.30 | 0.4355 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Morepen Laboratories Ltd | 1.20bn | 80.95m | 2.85bn | 1.62k | 32.69 | -- | 27.66 | 2.37 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 96.49m | -376.06m | 2.87bn | 205.00 | -- | 6.30 | -- | 29.80 | -0.7142 | -0.7142 | 0.1833 | 0.8664 | 0.1067 | 0.623 | 4.76 | 585,689.70 | -41.57 | -- | -45.49 | -- | 81.88 | -- | -389.75 | -- | 6.43 | -- | 0.3488 | -- | 88.31 | -- | -91.16 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Vokin Administra��o de Recursos LTDAas of 30 Jun 2024 | 1.23m | 0.68% |
| BTG Pactual WM Gest�o de Recursos Ltda.as of 30 Jun 2024 | 803.90k | 0.45% |
| Mellon Investments Corp.as of 03 Oct 2024 | 225.17k | 0.13% |
| BlackRock Brasil Gestora de Investimentos Ltda.as of 03 Oct 2024 | 215.08k | 0.12% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 200.00k | 0.11% |
| Apo Asset Management GmbHas of 31 Mar 2024 | 149.80k | 0.08% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 78.08k | 0.04% |
| Leblon Equities Gest�o de Recursos Ltda.as of 31 Jul 2023 | 76.89k | 0.04% |
| BB Gest�o de Recursos DTVM SAas of 30 Jun 2024 | 73.90k | 0.04% |
| Caixa DTVM SAas of 30 Jun 2024 | 73.70k | 0.04% |
